Cellect Biotechnology Ltd APOP is trading higher Monday after the company announced shareholder approval of the strategic merger with Quoin Pharmaceuticals.
Approximately 99% of the votes were in favor of approving the proposal. The strategic merger is expected to close in October.
Cellect Biotechnology is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies.
Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases.
APOP Price Action: Cellect Biotechnology is making new 52-week highs in trading today.
The stock was up 12.60% at $21.34 at time of publication.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
